A saúde bucal está diretamente relacionada à saúde corporal e doenças no corpo. Saiba mais no episódio de hoje.See omnystudio.com/listener for privacy information.

This PACUPod episode explores Schlueter et al.’s retrospective cohort study on a single fixed 4.5 mg intravenous dose of rasburicase for tumor lysis syndrome (TLS)–related hyperuricemia. Patients were stratified by baseline uric acid into moderate (12 to <15 mg/dL) and high (≥15 mg/dL) groups. The findings show rapid uric acid reduction in both groups, with no significant difference in clinical outcomes, suggesting that a fixed-dose approach could simplify dosing, reduce costs, and

The SMART-AI Project: Navigation and Support

Link to the preprint discussed: https://arxiv.org/pdf/2505.10251Link to the project with explanations: https://h-surgical-robot-transformer.github.io/A surgical robot that corrects its own mistakes sounds like science fiction.In this paper, new research from Johns Hopkins & Stanford makes it a reality. But is it ready for the operating room?The new SRT-H system allows a da Vinci robot to autonomously perform key steps of a gallbladder removal, achieving a 100% success rate in a lab setting. It

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 3-9, 2025: FDA Approves Fremanezumab to Prevent Episodic Migraine in Children The FDA has expanded fremanezumab’s indication

In this episode, Britany and Seth discuss Sachanas et al.'s retrospective case series of five patients with massive splenomegaly and prolymphocytosis who clinically resembled splenic marginal zone lymphoma (SMZL) but fulfilled criteria for B-cell prolymphocytic leukemia (B-PLL). Despite >55% circulating prolymphocytes, bone marrow infiltration and immunophenotyping were SMZL-like. No MYC rearrangements or TP53 deletions were found; one patient exhibited a 7q31 deletion, supporting

{"episode_description": "PACULit Daily Literature Update: Today we review a Phase 1b2 open-label multicenter trial evaluating cavrotolimod, a TLR9 agonist, in combination with anti-PD-1 antibodies (pembrolizumab or cemiplimab) for advanced cutaneous malignancies, including melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma. The study (NCT03684785) enrolled 58 adults with heavily pre-treated disease, beginning with cavrotolimod monotherapy dose escalation followed by

Welcome back to PACULit, your daily literature update for clinical pharmacists and physicians. Today we review a Phase III, triple-blind, placebo-controlled randomized trial evaluating photobiomodulation (PBM) to prevent chemotherapy-induced dysgeusia in breast cancer patients receiving doxorubicin–cyclophosphamide. The study directly compares a combined red plus infrared PBM protocol against single-wavelength PBM (red only or infrared only) to isolate each wavelength’s contribution

A concise overview of the first-in-human study of a no-alpha interleukin-2 (IL-2) mutein in patients with advanced solid tumors. The episode covers the rationale for avoiding IL-2 receptor alpha (CD25) to spare regulatory T cells, the phase I dose-escalation design, safety and pharmacodynamic findings showing selective activation of CD8+ T cells and NK cells, and the preliminary clinical signals. We discuss the implications for pharmacists and physicians, including dosing considerations,

This episode reviews the COAST trial, which evaluated durvalumab alone or in combination with two novel immunomodulators—oleclumab (anti-CD73) and monalizumab (anti-NKG2A)—as consolidation therapy after platinum-based concurrent chemoradiotherapy in unresectable stage III NSCLC. In this phase 2, open-label, randomized study (n=186), patients with ECOG 0–1 were assigned to durvalumab alone, durvalumab plus oleclumab, or durvalumab plus monalizumab for up to 12 months. The primary endpoint

Today on PACULit, we review the Phase 2 MonumenTAL-1 trial evaluating talquetamab, a bispecific antibody targeting GPRC5D and CD3, in relapsed or refractory multiple myeloma (RRMM). We discuss patient-reported outcomes and health-related quality of life data collected over up to ~42 weeks, using validated tools (EORTC QLQ-C30, EQ-5D-5L VAS, and PGIS). Key findings show an initial transient worsening in PROs during cycle 1, followed by meaningful improvements by cycle 21, including global

PACULit Daily Literature Update reviews the 5-year subgroup analysis of the ECHELON-2 trial focusing on frontline treatment for systemic anaplastic large cell lymphoma (sALCL). Hosted discussion covers study design (randomized, double-blind, active-controlled) and the sALCL patient cohort, comparing brentuximab vedotin plus CHP (BV+CHP) to CHOP. Key findings at five years include not reached median progression-free survival for BV+CHP vs 29.4 months for CHOP (hazard ratio 0.71, 95% CI

In this PACULit episode, Britany and Seth discuss a retrospective real-world study evaluating a single fixed 4.5 mg dose of rasburicase for TLS-related hyperuricemia. They explain stratification by baseline uric acid (moderate 12 to <15 mg/dL versus high ≥15 mg/dL) and report rapid uric acid reductions in both groups, with no significant differences in clinical outcomes. The discussion highlights potential cost savings, easier pharmacy workflows, and expanded access in resource-limited

In this PACULit episode, Britany and Seth discuss Sachanas et al.'s August 2025 study on B-cell prolymphocytic leukemia cases that mimic splenic marginal zone lymphoma. The hosts review how SMZL-like biology can occur within B-PLL phenotypes, evaluate Rituximab monotherapy as a safer alternative to chemotherapy or splenectomy, and emphasize the importance of comprehensive immunophenotyping and cytogenetics to guide therapy. Key findings include complete remission in 40% and prolonged

{ "episode_title": "PACULit Daily Literature Update: Cavrotolimod + Anti-PD-1 in Advanced Skin Cancers (Phase 1b2)", "episode_description": "Britany and Seth review a Phase 1b2 open-label trial evaluating intratumoral cavrotolimod, a TLR9 agonist, in combination with systemic anti-PD-1 antibodies (pembrolizumab or cemiplimab) in 58 patients with advanced or metastatic melanoma, Merkel cell carcinoma, or cutaneous squamous cell carcinoma who largely progressed on prior anti-PD-(L)1

The Pediatric Breathing Project with Dr. Piya Gandhi is a groundbreaking podcast dedicated to one of the most overlooked foundations of childhood health: breathing. Hosted by Dr. Piya Gandhi, DDS—functional pediatric dentist and airway health advocate—this show explores the vital connection between oral development, jaw growth, sleep, and overall wellness. From mouth breathing and snoring to pediatric sleep apnea, Dr. Gandhi breaks down the science in a way that parents, caregivers, and healt...

Medicine with Meaning is the podcast for people who believe health is more than lab results and quick fixes. Hosted by Dr. Julie Taw – a physician who blends clinical expertise with a soulful lens – this show explores the connection between body, mind, and spirit. Each episode unpacks the science behind your symptoms while uncovering the deeper meaning they carry for your life, purpose, and growth. Listeners walk away with evidence-based strategies they can trust, paired with heart-centered w...

Malaria remains a global health challenge, and in recent days, several developments have emerged in both the fight against the disease and the ongoing rollout of vaccines. On August 8, it was reported by The World that Ghana has approved the world's first malaria drug specifically for newborns. The medication, called Coartem Baby, is the result of nearly a decade of research and dissolves in breast milk, making it both safe and effective for infants. This marks a major advance in infant malaria

Pearls for Parkinson's: Tips for Daily Living with PD. This week's tip is on cutting medication costs. To watch this episode on YouTube: https://youtu.be/YU36xZs3Yoc To support more programs like this: https://wiparkinson.app.neoncrm.com/forms/support-pearls4pd Wisconsin Parkinson Association website: https://wiparkinson.org/ YouTube: https://www.youtube.com/@wiparkinson facebook: https://www.facebook.com/wiparkinson/ instagram: https://www.instagram.com/wiparkinson/